Gynecomastia

NYC Plastic Surgeon, Dr. Aleksandr Shteynberg, acknowledged as a Top Patient Rated New York Plastic Surgeon for 2024 by Find Local Doctors

Retrieved on: 
Monday, February 12, 2024

NEW YORK, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Dr. Aleksandr Shteynberg, M.D., FACS, a distinguished plastic surgeon renowned for his expertise in breast, body, facial and reconstructive surgeries facial, body, and reconstructive surgeries, has been honored as a Top Patient Rated New York Plastic Surgeon for 2024 by Find Local Doctors. This prestigious recognition comes as a result of Dr. Shteynberg's outstanding reviews from satisfied patients across various online platforms.

Key Points: 
  • Find Local Doctors has recognized renowned plastic surgeon, Dr. Aleksandr Shteynberg, as a 2024 Top Patient Rated New York Plastic Surgeon due to his large volume of five-star reviews from patients across multiple online sources.
  • NEW YORK, Feb. 12, 2024 /PRNewswire-PRWeb/ -- Dr. Aleksandr Shteynberg, M.D., FACS, a distinguished plastic surgeon renowned for his expertise in breast, body, facial and reconstructive surgeries facial, body, and reconstructive surgeries, has been honored as a Top Patient Rated New York Plastic Surgeon for 2024 by Find Local Doctors .
  • Find Local Doctors, an esteemed online directory connecting consumers with highly skilled physicians, has highlighted Dr. Shteynberg's exceptional reputation within the field of plastic surgery.
  • "It's a privilege to be recognized as a Top Patient Rated Plastic Surgeon for 2024," says Dr. Shteynberg.

Dr Ivan Puah Designs Tailored Surgical Technique To Address Bodybuilders' Prominent Breast Deformity Issue

Retrieved on: 
Tuesday, December 12, 2023

Among those who engage in such practices, some have developed breast deformity called gynecomastia or enlarged male breasts.

Key Points: 
  • Among those who engage in such practices, some have developed breast deformity called gynecomastia or enlarged male breasts.
  • Anabolic steroids cause male breast enlargement, a type of breast deformity in men.
  • To address this, Dr. Ivan Puah developed the 360 degrees Glandular Tissue Dissection (360 degrees GTD®) technique.
  • With the introduction of our 360 degrees Glandular Tissue Dissection, we can help these affected athletes," Dr Ivan Puah explained.

Amaris B. Clinic Unveils Unique Gynecomastia Insights From 554 Patients In Singapore

Retrieved on: 
Wednesday, October 25, 2023

Clinic to be recognised as the "Gynecomastia Clinic of the Year in APAC" at the Asia-Pacific Specialist Clinic and Medical Centre Awards in May 2023.

Key Points: 
  • Clinic to be recognised as the "Gynecomastia Clinic of the Year in APAC" at the Asia-Pacific Specialist Clinic and Medical Centre Awards in May 2023.
  • Clinic undertook an extensive analysis of 554 patients who had gynecomastia surgery done by Dr Ivan Puah between January 2018 and July 2023.
  • Clinic Singapore
    The mean age of the 554 patients Dr Ivan Puah has successfully treated for gynecomastia from January 2018 to July 2023 is 32.
  • Average BMI of gynecomastia patients at Amaris B.

Nymox Update

Retrieved on: 
Thursday, July 13, 2023

IRVINE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing additional information concerning recent changes in the Company’s board of directors (the “Board”) and management, as well as additional information regarding the Company’s conclusion that a potential transaction was not in the best interests of the Nymox and its shareholders.

Key Points: 
  • IRVINE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing additional information concerning recent changes in the Company’s board of directors (the “Board”) and management, as well as additional information regarding the Company’s conclusion that a potential transaction was not in the best interests of the Nymox and its shareholders.
  • Nymox recently terminated the employment of Mr. Randall Lanham, the Company’s former in-house legal counsel, and Mr. Christopher Riley, the Company’s former chief financial officer.
  • Mr. Lanham (legal counsel) and Mr. Riley (CFO) previously presented Nymox with a transaction with a potential business partner (the “Proposed Transaction”).
  • Dr. Paul Averback, CEO of Nymox said, "Our fiduciary responsibilities are first and foremost to the shareholders of Nymox, and the above terms were not in the best interests of Nymox shareholders.

Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox

Retrieved on: 
Wednesday, July 12, 2023

IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors.

Key Points: 
  • IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors.
  • Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in the Intellectual Property Group, and currently is Senior Counsel.
  • Mr. Doody has represented Nymox and its predecessor company in intellectual property matters for over 30 years, securing hundreds of issued patents for Nymox throughout the world.
  • Dr. Paul Averback CEO and Chairman of Nymox said, "Patrick brings with him decades of experience with industry and in legal intellectual property practice.

NYMOX Update

Retrieved on: 
Friday, July 7, 2023

IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors (“Board”) and the Company’s management.

Key Points: 
  • IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors (“Board”) and the Company’s management.
  • Two former employees (the “Former Employees”) of the Company proposed to the Company a potential transaction (the “Proposed Transaction”).
  • The Company, its employees, and the Former Employees are bound by an obligation not to disclose any details of the Proposed Transaction.
  • Nymox is in the process of submitting applications for the approval to market the Company's first in class drug NYMOZARFEX to treat the symptoms of benign prostatic hyperplasia (BPH).

Nymox Delisting from NASDAQ

Retrieved on: 
Wednesday, July 5, 2023

Dr. Paul Averback, CEO of Nymox said, "This is a key time for the Company, with more than one important marketing application being submitted. We are grateful to our loyal shareholders for their patience and we wish to assure our supporters that we are doing our best to deliver important milestones in our business development, in as reasonable a time horizon as possible. It took a long time to get to this point but we believe enhanced fundamental value has been developed -- and we intend to continue to do everything in our power to deliver the goods to the public and to our stakeholders."

Key Points: 
  • IRVINE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023.
  • Nymox shares will be moved to the OTC market.
  • Nymox is in the process of submitting applications for the approval to market the Company's first in class drug NYMOZARFEX to treat the symptoms of benign prostatic hyperplasia (BPH).
  • Dr. Paul Averback, CEO of Nymox said, "This is a key time for the Company, with more than one important marketing application being submitted.

BCFFR in Boston Named Castle Connolly Top Doctors for 2023

Retrieved on: 
Friday, March 31, 2023

BOSTON, March 31, 2023 /PRNewswire-PRWeb/ -- The elite team of physicians at BCFFR, Leonard B. Miller, MD - Plastic Surgery, Sean T. Doherty, MD - Plastic Surgery, Melissa A. Michelon, MD - Dermatology, and Farah Moustafa, MD - Dermatology, are honored to be listed in Castle Connolly America's Top Doctors again in 2023 in recognition of their commitment to excellence in medicine and patient care.

Key Points: 
  • Boston Center for Facial Rejuvenation in Boston, MA, is one of the longest-standing medical practices in Boston, offering advanced cosmetic and medicinal treatments.
  • It is an honor for BCFFR to be listed again among Castle Connolly America's Top Doctors.
  • 2023 is the 30th anniversary of Castle Connolly Top Doctors, representing the top seven percent of all physicians nationwide.
  • Miller and Doherty are Castle Connolly America's Top Doctors for 2023, featured in Boston Magazine's Top Doctors for 2023, and recognized by RealSelf, Vitals, and America's Best Physicians.

The Latest Global Survey from ISAPS Reports a Significant Rise in Aesthetic Surgery Worldwide

Retrieved on: 
Monday, January 23, 2023

MOUNT ROYAL, N.J., Jan. 9, 2023 /PRNewswire/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures today, showing a 19.3% overall increase in procedures performed by plastic surgeons in 2021 with more than 12.8 million surgical, and 17.5 million non-surgical, procedures performed worldwide.

Key Points: 
  • The report shows a continuing rise in Aesthetic Surgery with a 33.3% increase over the last four years.
  • Both surgical and non-surgical procedures showed increases since the last survey (18.5% and 19.9% respectively) with a significant increase of 54.4% in non-surgical procedures in the last four years.
  • The top five most popular surgical procedures remain liposuction, breast augmentation, eyelid surgery, rhinoplasty, and abdominoplasty.
  • Breast augmentation remains the most common surgical procedure for women, with only a slight increase of +0.5% in the last four years.

The Latest Global Survey from ISAPS Reports a Significant Rise in Aesthetic Surgery Worldwide

Retrieved on: 
Monday, January 9, 2023

MOUNT ROYAL, N.J., Jan. 9, 2023 /PRNewswire/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures today, showing a 19.3% overall increase in procedures performed by plastic surgeons in 2021 with more than 12.8 million surgical, and 17.5 million non-surgical, procedures performed worldwide.

Key Points: 
  • The report shows a continuing rise in Aesthetic Surgery with a 33.3% increase over the last four years.
  • Both surgical and non-surgical procedures showed increases since the last survey (18.5% and 19.9% respectively) with a significant increase of 54.4% in non-surgical procedures in the last four years.
  • The top five most popular surgical procedures remain liposuction, breast augmentation, eyelid surgery, rhinoplasty, and abdominoplasty.
  • Breast augmentation remains the most common surgical procedure for women, with only a slight increase of +0.5% in the last four years.